论文部分内容阅读
应用ＨＥＶ基因结构区的重组融合蛋白，建立了免疫吸印法（ＷｅｓｔｅｒｎＢｌｏｔ．ＷＢ）检测抗－ＨＥＶＩｇＧ，并与现行的酶联免疫试验（ＥＩＡ）进行了比较。结果表明，ＷＢ检出戊型肝炎暴发点急性肝炎病人血清抗－ＨＥＶＩｇＧ的阳性率（６８／７３，９３．２％）高于现行的ＥＩＡ（５１／７３，７００％），对实验感染猕猴抗－ＨＥＶＩｇＧ检出率前者也高于后者（分别为７／７和５／７），且检出抗－ＨＥＶＩｇＧ时间较长，滴度也较高。对多种对照血清检测结果表明，除５０％（３／５８）的丙型肝炎血清呈阳性外，甲型、乙型、ＥＢＶ、ＣＷＶ肝炎及健康人血清均为阴性，说明该法具有良好的灵敏度和特异性，可望用于流行病学调查和基础研究，也可用于疑是戊型肝炎病例的确诊
The recombinant fusion protein of HEV gene region was used to detect anti-HEVIgG by Western Blot.WB and compared with the current EIA. The results showed that the positive rate of serum anti-HEVIgG (68/73, 93.2%) in WB patients with hepatitis E outbreak was higher than that of the current EIA (51/73, 700%), -HEVIgG detection rate of the former is also higher than the latter (7/7 and 5/7, respectively), and the detection of anti-HEVIgG is longer and the titer is also higher. The test results of a variety of control sera showed that the serums of type A, B, EBV, CWV hepatitis and healthy human were all negative except that 50% (3/58) of the serum of hepatitis C were positive, which indicated that the method had good Sensitivity and specificity, is expected to be used for epidemiological investigations and basic research, but also for the suspected diagnosis of hepatitis E cases